Abstract
Intragastric balloons (IGB) were FDA-approved in 2015 for treatment of patients with obesity. In the first reported US clinical experience (30 patients, presented at OW2016), our findings indicated that IGB is an effective minimally-invasive obesity treatment. The effect of pharmacotherapy intervention on weight loss maintenance after intragastric balloon removal is unknown.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
